The virulent surge of COVID-19 in Karnataka showed no signs of abating during the lockdown, with the State showing a sharp 31% rise in number of positive cases reported between April 27 and May 7.Whil
Synopsis
The experts will decide whether to keep the interval as it is, shorten it, or increase the gap, people in the know told ET. “The decision will be taken keeping in mind vaccine coverage and breakthrough infections,” said a government official.
PTI
The experts will review the evidence from other countries.
The National Technical Advisory Group on Immunisation (NTAGI), an advisory committee, will meet next week to review the vaccine dosage interval of Covishield, the Covid-19 vaccine from Serum Institute of India (SII). The experts will decide whether to keep the interval as it is, shorten it, or increase the gap, people in the know told ET. “The decision will be taken keeping in mind vaccine coverage and breakthrough infections,” said a government official.
Balbir Singh gently places the last of the wood slabs over his 27-year-old sonâs unlit pyre. He observes it for a moment and then walks around to the other side and carefully replaces a loose slab. He looks around perplexed, as if wondering if someone will show him what to do next. âI have never had to set alight a pyre by myself before. He was supposed to light mine,â he says, trying to hold back the tears, as they roll into the mask hanging loosely over his nose. He is Covid-positive too.
Itâs 12.30pm and Balbir is at New Delhiâs Seemapuri crematorium. He spent the previous night running from hospital to hospital. His son Sagarâs oxygen saturation levels had fallen precipitously by early evening, dipping to 60, 25 points below normal. With no doctors answering calls, and the government helplines constantly busy, Balbir took matters into his own hands. Unable to get an ambulance, he relied on the generosity of an auto rickshaw driver in his neighbo
May 08, 2021 08:12
The World Health Organization has approved a COVID-19 vaccine developed in China for emergency use worldwide. The vaccine, from China s state-owned drugmaker Sinopharm, is the first vaccine manufactured by a non-Western country to be endorsed by WHO.
Friday s move was also the first time the global public health group granted emergency approval to a Chinese vaccine for an infectious disease. China s Sinopharm COVID-19 vaccine has already been administered to hundreds of millions of people in China and in other parts of the world, along with a second Chinese vaccine.
WHO s decision allows the Sinopharm vaccine to be included in COVID-19 Vaccines Global Access, or COVAX, an initiative to distribute vaccines to mainly poor countries. WHO has said it could decide on China s second main vaccine, made by Sinovac Biotech, as early as next week.
May 8, 2021 Share
The World Health Organization (WHO) has approved a COVID-19 vaccine developed in China for emergency use worldwide.
The vaccine, from China’s state-owned drugmaker Sinopharm, is the first vaccine manufactured by a non-Western country to be endorsed by WHO.
Friday’s move was also the first time the global public health group granted emergency approval to a Chinese vaccine for an infectious disease.
China’s Sinopharm COVID-19 vaccine has already been administered to hundreds of millions of people in China and in other parts of the world, along with a second Chinese vaccine.
WHO’s decision allows the Sinopharm vaccine to be included in COVID-19 Vaccines Global Access, or COVAX, an initiative to distribute vaccines to mainly poor countries.